Safety, immunogenicity and clinical efficacy of an allergen vaccine (AllQbG10) in subjects with allergic rhino-conjunctivitis and asthma due to house dust mite allergy
Phase of Trial: Phase I/II
Latest Information Update: 26 Apr 2008
At a glance
- Drugs CYT 005 AllQbG10 (Primary)
- Indications Asthma; Rhinoconjunctivitis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Cytos Biotechnology
- 26 Apr 2008 New trial record.
- 14 Dec 2005 Primary endpoint 'Immunological response' has been met.